prophylaxis with fondaparinux is cost-effective was addressed in this study. METHODS: A decision analytic model was developed to compare a four-week fondaparinux regimen with a one-week regimen. Clinical input parameters were derived from clinical trials and other published sources. Cost data for Swiss university hospitals were obtained from the single service tariffs database (Tarmed), the Swiss Drugs Compendium and the diagnosis related groups database (AP-DRG) and were expressed in 2004 Swiss francs (CHF). The model simulates a cohort of HFS and THR patients over 30 days and 5 years. Outcomes were measured in life-years gained (LYG). Future costs and outcomes were discounted with an annual rate of four percent. RESULTS: In a hypothetical cohort of 1000 HFS patients, extended prophylaxis avoids 10 fatal events and 9 VTEs over a time horizon of 30 days. The corresponding ICER is CHF 2801 per LYG. With a lower baseline risk for VTE in THR patients, extended fondaparinux prophylaxis prevents one fatal event in 1000 patients over a time horizon of 30 days, yielding an ICER of CHF20,294 per LYG. After five years, extended prophylaxis is cost saving in both HFS and THR patients. The model results were robust to variations of major clinical and cost parameters. CONCLU-SIONS: Extended prophylaxis with fondaparinux in THR and HFS patients is cost-effective from a Swiss health care perspective using a time horizon of 30 days. With a longer time horizon of five years, extended prophylaxis with fondaparinux is cost-saving.
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PCV90 COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS
Van Hout B Pharmerit BV, Rotterdam, The Netherlands OBJECTIVE: To determine the cost-effectiveness of fondaparinux compared with enoxaparin for extended prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery using Dutch estimates of costs. METHODS: Costs and effects are modeled using a cohort simulation model. Short term transition probabilities (until day 30) are based from placebo controlled trials. Long term probabilities are obtained from the literature. Resource use and costs were obtained from a Dutch costing study concerning bleedings and symptomatic events. Outcome measures were rates of symptomatic thromboembolic events, deaths avoided and health care costs. Costs were in 2003 values. "Confidence intervals" (CI) are obtained by probabilistic sensitivity analysis. RESULTS: Fondaparinux was estimated to prevent an additional 158 symptomatic venous thromboembolic events (per 10,000 patients) at 1 year after major orthopaedic surgery compared with enoxaparin (95% CI:163-371). The cost savings (per patient) of using fondaparinux over enoxaparin are estimated at €103 (€34-€178). The number of deaths avoided (per 10,000 patients) is estimated at 103 (57-165). The probability that fondaparinux is both more effective and cost saving is estimated at 0.9996. CONCLUSION: Extended prophylaxis with fondaparinux after major orthopedic surgery can be expected to result in both better outcomes and cost savings when compared with extended prophylaxis with enoxaparin.
PCV91 COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS
Van Hout B Pharmerit BV, Rotterdam, The Netherlands OBJECTIVE: To determine the cost effectiveness of extended prophylaxis with fondaparinux to prevent venous thromboembolism in patients undergoing hip fracture surgery compared to short term using UK and Dutch estimates of costs. METHODS: Costs and effects are modeled using a cohort simulation model. Short term transition probabilities (until day 30) are obtained from placebo controlled trials. Long term probabilities are obtained from the literature. UK resource use and costs were obtained from a published analysis concerning short term prophylaxis. Dutch resource use and costs were estimated in a separate costing study concerning bleedings and symptomatic events. Outcome measures were rates of symptomatic thromboembolic events, deaths avoided and health care costs. Costs were in 2004 values. "Confidence intervals" (CI) were obtained by probabilistic sensitivity analysis. RESULTS: At one year extending prophylaxis with fondaparinux after major orthopaedic surgery from 7 to 22 days was estimated to prevent 343 symptomatic venous thromboembolic events (per 10,000 patients) (95% CI:283-391). The additional cost (per patient) of extending the prophylactic period is estimated at £164 (£117-£212) in the UK and at €66 in The Netherlands. The number of deaths avoided (per 10,000 patients) is estimated at 138 (89-192) . Costs per symptomatic VTE avoided are estimated at £4,788 (£3258-£6906) in the UK and at €1915 (€392-€4021) in The Netherlands. Costs per death avoided are estimated at £11,932 (£7220-£20,480) and €4773 (€892-€11,629). When assuming the average survival after surgery at 6 years, costs per life year gained are estimated at under £3,000 for the UK and at under €900 for The Netherlands. CONCLUSION: Our estimates indicate that extending the prophylaxis with fondaparinux from 7 to 21 days has an acceptable balance between cost and outcomes both in the UK and The Netherlands. Oral anticoagulation is indicated for a number of conditions, including prevention of systemic embolism in patients with mechanical heart valves, valvular heart disease, myocardial infarction and atrial fibrillation. VKA are frequently prescribed as long term treatment. Due to the features of treatment, VKA have the potential to cause dissatisfaction and reduce QoL. OBJECTIVES: To assess Health-Related Quality of life (HRQOL) in patients receiving VKA comparing their health status with matched controls. METHODS. Ninety-two consecutive patients receiving VKA (53 male; age range 37-81 years) were enrolled among those followed by our anticoagulation clinic. The more frequent indications for VKA treatment were atrial fibrillation and venous thromboembolism. Each patient was matched by age and sex with one control from a database of a population based naturalistic prospective survey. The EuroQoL, completed during the enrolment visit, was used to evaluate HRQOL. To evaluate differences in the five dimensions between the two groups was used Chi Square Test. To evaluate differences in EQ VAS was used both Paired sample T test and a regression analysis using bootstrap estimated of standard error. RESULTS: No statistically significant differences were reported in all dimensions between the two groups: mobility (P = 1.000), self care (P = 0.064), usual activities (P = 0.213), pain/discomfort (P = 0.213) and anxiety/depression (P = 0.512). The figures obtained using VAS to assess the global health status was: 72.8 (SD, ± 19.7) in patients treated with VKA and 73.9 (SD, ± 16.0) in matched controls; this difference was not statistically significant (p = 0.708 Paired sample T); also bootstrap confident intervals indicated that there was no statistically significant differences between the two groups. CONCLUSIONS: Even if it is conceivable that different settings would give different results, our study show that in patients on oral anticoagulant treatment the overall perception of health status was not significantly different from that of matched controls. (QoL) measures, that are not preference based, and thus lack legitimacy for direct use in economic evaluations, has prompted a need for modeling to derive utilities. The QoL Assessment of Growth Hormone Deficiency in Adults questionnaire (QoL-AGHDA) is a disease-oriented measure used to assess impairment in QoL in adults with growth hormone deficiency. The present study aims to provide a model for deriving utilities directly from the QoL-AGHDA. METHODS: The EQ-5D and the QoL-AGHDA were mailed to a random sample (n = 2990) of the Swedish population (response rate, 65%). The Jack knife method was used to obtain cross-validated parameters of QoL-AGHDA-based utilities. Using the EQ-5D index (derived from European values) as the dependent variable, and age, gender and QoL-AGHDA score as independent variables in repeated regression analyses, each time omitting one tenth of the sample (the Jack-knife method) estimates for the coefficients for transformation of the QoL-AGHDA into a single score (range, 0-1) were achieved. These transformed QoL-AGHDA scores correspond to the QoL-AGHDA-based utility. RESULTS: The transformation algorithm was: U (QoL-AGHDA-based utilities) = [102.2 -1.80*QoL-AGHDA score -0.227 * age -1.21*Gender (men = 0; women = 1)]/100. The mean of the weighted estimate for the total population (n = 1752) was 0.83 (SD, 0.09). The estimate for men (n = 861; mean, 0.84; SD, 0.09) was higher (p < 0.001) than for women (n = 891; mean, 0.82; SD, 0.09). CONCLUSION: The present model could be used to derive utilities directly from the QoL-AGHDA; however, it should be highlighted that the coefficients presented here come from the homogeneous Swedish population and thus application to other populations should be carefully considered. 4 Uppsala University, Uppsala, Sweden Although the beneficial effect of growth hormone replacement on QoL in adults with GHD is well recognized, the long-term effect of this therapy on QoL remains uncertain. OBJECTIVES: To determine the effect of long term GH replacement on QoL in patients compared with country-specific normative data for the general population (GP). METHODS: QoL was measured using Quality of Life Assessment for Growth Hormone Deficiency in Adults (QoL-AGHDA) in patients and GP in Sweden and England & Wales (E&W). QoL-AGHDA is a 25-item questionnaire that elicits yes/no responses that are used to compute a summary score. GP data were obtained from 1682 randomly selected individuals from Sweden and 892 from E&W. These data were compared with KIMS (Pfizer International Metabolic Database) data for 121 patients from Sweden and 77 from E&W with 5 years of complete follow-up. Age-range was 20-79 years. Linear regression methods were used to estimate age-and gender-adjusted differences between patients and the GP at oneyear intervals. The significance level was set at 5%. RESULTS: The (adjusted to age 50) mean QoL-AGHDA score at baseline were 8.21 and 15.2 (SEM 0.44 and 0.68) for the Swedish and E&W patients, respectively. For the GP samples the corresponding mean scores were 3.80 and 6.6 (SEM 0.12 and 0.20). The mean difference between patient scores at baseline and GP scores were -4.4 for Sweden and -8.6 for E&W (p < 0.0001). However, these differences reduced markedly over the first year of treatment and were subsequently maintained at statistically non-significant differences compared to the general populations. CONCLUSIONS: This study shows that adults with GHD who receive long-term GH replacement benefit most with respect to QoL during the first 12 months of therapy and that this improvement was maintained at levels close to normalization in QoL over 5 years of follow up.
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